Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxyge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:N Engl J Med
Hauptverfasser: Goldman, Jason D., Lye, David C.B., Hui, David S., Marks, Kristen M., Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D., Galli, Massimo, Ahn, Mi-Young, Nahass, Ronald G., Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M., Towner, William J., Muñoz, Jose, Mullane, Kathleen M., Marty, Francisco M., Tashima, Karen T., Diaz, George, Subramanian, Aruna
Format: Artigo
Sprache:Inglês
Veröffentlicht: Massachusetts Medical Society 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7377062/
https://ncbi.nlm.nih.gov/pubmed/32459919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2015301
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge